Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment - PubMed (original) (raw)

Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment

Steven A Rosenberg. Nat Rev Clin Oncol. 2014 Nov.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

The author declares no competing interests.

Figures

Figure 1 |

Adoptive cell transfer immunotherapy. Cells are obtained from a resected tumour (autologous TILs) or using peripheral lymphocytes genetically engineered to express antitumour T-cell receptors, expanded in vitro and infused to patients after they have received a preparative lymphodepleting regimen. Abbreviation: TIL, tumour-infiltrating lymphocyte.

Similar articles

• Immunotherapy of cancer: a critical review.
  Lutz D. Lutz D. Int J Clin Pharmacol Ther Toxicol. 1983 Mar;21(3):118-29. Int J Clin Pharmacol Ther Toxicol. 1983. PMID: 6343261 Review.
• [Immunotherapy of cancer].
  Lascano FD, Mazzei JA, Estevez ME. Lascano FD, et al. Prensa Med Argent. 1971 Mar 12;58(2):75-91. Prensa Med Argent. 1971. PMID: 4103879 Review. Spanish. No abstract available.
• Current aspects of immunotherapy in cancer.
  [No authors listed] [No authors listed] Langenbecks Arch Chir. 1981;354(1):1-17. doi: 10.1007/BF01834012. Langenbecks Arch Chir. 1981. PMID: 7253782 English, German. No abstract available.
• [Immunotherapy of hemato-oncologic diseases].
  Winkler U, Bohlen H, Schirrmacher V, Schlimok G, Voliotis D, Brach M, Niederle N, Tesch H, Diehl V, Engert A. Winkler U, et al. Med Klin (Munich). 1996 Apr 10;91(4):226-33. Med Klin (Munich). 1996. PMID: 8692109 Review. German. No abstract available.
• [The immunotherapeutic approaches to the management of leukemia and neoplasms].
  Leu TP. Leu TP. Zhonghua Yi Xue Za Zhi. 1974 May;5:310-4. Zhonghua Yi Xue Za Zhi. 1974. PMID: 4211699 Chinese. No abstract available.

Cited by

• Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
  Li YF, Hou QQ, Zhao S, Chen X, Tang M, Li L. Li YF, et al. J Cancer Res Clin Oncol. 2023 Feb;149(2):623-637. doi: 10.1007/s00432-022-04285-7. Epub 2022 Oct 14. J Cancer Res Clin Oncol. 2023. PMID: 36239794 Free PMC article.
• Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies.
  De Sousa PA, Ritchie D, Green A, Chandran S, Knight R, Head MW. De Sousa PA, et al. Acta Neuropathol. 2019 Mar;137(3):363-377. doi: 10.1007/s00401-018-1941-9. Epub 2018 Nov 27. Acta Neuropathol. 2019. PMID: 30483944 Free PMC article. Review.
• PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy.
  Jassim BA, Lin J, Zhang ZY. Jassim BA, et al. Expert Opin Drug Discov. 2022 Aug;17(8):825-837. doi: 10.1080/17460441.2022.2084607. Epub 2022 Jun 7. Expert Opin Drug Discov. 2022. PMID: 35637605 Free PMC article. Review.
• Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.
  Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Fasano R, et al. Life (Basel). 2021 Dec 7;11(12):1355. doi: 10.3390/life11121355. Life (Basel). 2021. PMID: 34947886 Free PMC article. Review.
• Immunotherapy in breast cancer.
  Bayraktar S, Batoo S, Okuno S, Glück S. Bayraktar S, et al. J Carcinog. 2019 May 23;18:2. doi: 10.4103/jcar.JCar_2_19. eCollection 2019. J Carcinog. 2019. PMID: 31160888 Free PMC article. Review.

References

1. 1. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 363, 711–723 (2010). - PMC - PubMed
2. 1. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 366, 2443–2454 (2012). - PMC - PubMed
3. 1. Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 366, 2455–2465 (2012). - PMC - PubMed
4. 1. Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med 363, 422 (2010). - PubMed
5. 1. Rosenberg SA et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res 17, 4550–4557 (2011). - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information